Ulocuplumab
- CAS No.
- 1375830-34-4
- Chemical Name:
- Ulocuplumab
- Synonyms
- Ulocuplumab;BMS 936564|||MDX 1338;Ulocuplumab (anti-CXCR4);Research Grade Ulocuplumab;Research Grade Ulocuplumab(DHF39901)
- CBNumber:
- CB08080897
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 7KNP87L4X4 |
| NCI Drug Dictionary | ulocuplumab |
Ulocuplumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0620946 | Ulocuplumab 99.90% | 1375830-34-4 | 1mg | $282 | 2026-06-04 | Buy |
| ChemScene | CS-0620946 | Ulocuplumab 99.90% | 1375830-34-4 | 5mg | $845 | 2026-06-04 | Buy |
| ChemScene | CS-0620946 | Ulocuplumab 99.90% | 1375830-34-4 | 10mg | $1354 | 2026-06-04 | Buy |
| ChemScene | CS-0620946 | Ulocuplumab 99.90% | 1375830-34-4 | 25mg | $2437 | 2026-06-04 | Buy |
| ChemScene | CS-0620946 | Ulocuplumab 99.90% | 1375830-34-4 | 50mg | $3900 | 2026-06-04 | Buy |
Ulocuplumab Chemical Properties, Uses, Production
Uses
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models[1][2].
in vivo
Ulocuplumab (3-30 mg/kg; i.p.; every 3-4 days for 5 doses; 65 days in total) inhibits tumor growth of multiple myeloma xenograft models in mice, including Ramos B cells, HL-60 cells, MOLP-8 cells, Nomo-1 cells, and JJN-3R cells models[1].
| Animal Model: | Severe combined immunodeficient (SCID) mice of AML model (MOLP-8 cells)[1] |
| Dosage: | 3-30 mg/kg |
| Administration: | Intraperitoneal injection; every 3-4 days for 5 doses; last for 65 days |
| Result: | Significantly delayed mean tumor growth by 66% and 56% when compared with isotype control on day 25. |
IC 50
CXCR4
References
[1] Kashyap MK, et al. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19;7(3):2809-22. DOI:10.18632/oncotarget.6465
[2] Kuhne MR, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19(2):357-66. DOI:10.1158/1078-0432.CCR-12-2333
Ulocuplumab Preparation Products And Raw materials
Raw materials
Preparation Products
Ulocuplumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
View Latest Price from Ulocuplumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Ulocuplumab
1375830-34-4
|
$213.00-987.00 | 97.5% (SDS-PAGE); 96.2% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Ulocuplumab
1375830-34-4
- $213.00-987.00
- 97.5% (SDS-PAGE); 96.2% (SEC-HPLC)
- TargetMol Chemicals Inc.
